HIV prevention has changed significantly with the development of long-acting antiretroviral medicines. Traditional prevention strategies have included condoms, HIV testing, post-exposure prophylaxis, and oral pre-exposure prophylaxis, commonly called PrEP. Newer approaches are designed to reduce the need for frequent daily medication. The phrase “HIV protection implant” is sometimes used when discussing long-lasting HIV prevention technologies. However, it is important to distinguish an implant from a long-acting injection. Current HIV prevention developments include injectable medicines such as lenacapavir and cabotegravir, while implant-based systems remain an area of research rather than a standard form of HIV prevention.
An HIV prevention implant would be a small device placed beneath the skin and designed to release an antiretroviral medicine gradually.
Instead of taking a pill each day or receiving periodic injections, an implant could potentially provide medication continuously for a longer period.
The concept is similar to other types of medication implants used in medicine. A small device can act as a drug reservoir, releasing controlled quantities of medication over time.
For HIV prevention, the objective would be to maintain sufficient antiretroviral drug concentrations in the body to prevent HIV from establishing an infection following exposure.
However, HIV prevention implants should not be confused with currently approved long-acting injectable PrEP medicines.
No. Implant-based HIV prevention is still an area of research.
Long-acting injectable PrEP has progressed much further. WHO currently recognizes long-acting injectable cabotegravir and lenacapavir among recommended PrEP approaches, alongside oral PrEP and the dapivirine vaginal ring.
In the United States, lenacapavir has been approved as a twice-yearly injectable PrEP medicine for reducing the risk of sexually acquired HIV-1.
Therefore, articles describing a “six-month HIV implant” or similar technology should be interpreted carefully. A twice-yearly injection is not the same as a physical implant placed under the skin.
PrEP stands for pre-exposure prophylaxis.
It involves using antiretroviral medication before potential exposure to HIV. The medicine works by preventing HIV from establishing a productive infection if exposure occurs.
PrEP is intended for people who do not have HIV.
Different PrEP medicines work through different mechanisms, but the overall goal is the same: maintain sufficient levels of medication so that HIV replication can be blocked if exposure occurs.
PrEP is one component of a broader HIV prevention strategy that can also include condoms, HIV testing, treatment of sexually transmitted infections, and other risk-reduction measures.
Daily medication can be highly effective when taken consistently, but maintaining a daily routine can be difficult for some people.
Reasons can include:
An implant could potentially address some of these barriers by providing continuous drug delivery without requiring daily tablets.
Researchers are therefore studying ways to deliver antiretroviral medicines through long-lasting implants or other drug-delivery technologies.
A potential HIV prevention implant would contain an antiretroviral medicine.
After placement beneath the skin, the device could gradually release the medication into the surrounding tissue and bloodstream.
The release rate would need to remain sufficiently stable to maintain protective drug concentrations.
The ideal system would provide predictable medication exposure for an extended period while minimizing fluctuations in drug levels.
At the end of the intended treatment period, the implant could potentially be removed or replaced, depending on the technology.
Developing such a system presents several scientific and medical challenges.
The central idea behind long-acting HIV prevention is reducing the frequency of medication administration.
A daily pill requires repeated adherence. An injection administered at longer intervals reduces the number of dosing events.
An implant could theoretically extend this interval even further.
For HIV prevention, maintaining consistent drug exposure is particularly important because protection depends on having sufficient antiretroviral activity when exposure to HIV occurs.
A long-acting approach could therefore help reduce problems associated with missed daily doses.
Lenacapavir is one of the most significant developments in long-acting HIV prevention.
It belongs to a class of medicines called capsid inhibitors. Rather than targeting one of the traditional HIV enzymes, lenacapavir interferes with the viral capsid, a protein structure involved in several stages of the HIV life cycle.
The prevention formulation is administered by subcutaneous injection rather than implantation.
The regimen is designed around twice-yearly administration, making it substantially less frequent than daily oral PrEP.
This distinction is important when discussing HIV prevention implants because lenacapavir is sometimes described in general media coverage as a long-lasting HIV prevention treatment, even though it is administered as an injection rather than a physical implant.
Cabotegravir is another long-acting injectable medicine used for HIV PrEP in certain settings.
Unlike daily oral PrEP, long-acting cabotegravir is administered through scheduled injections.
The development of cabotegravir demonstrated that HIV prevention can be delivered through a long-acting injectable approach rather than relying exclusively on daily tablets.
WHO includes long-acting injectable cabotegravir among its recommended PrEP methods.
The emergence of injectable PrEP has also helped advance interest in even longer-duration drug-delivery technologies.
The two technologies are fundamentally different.
A long-acting injection delivers medication through a needle into tissue beneath the skin or into muscle, depending on the medicine.
The medication gradually enters the body and can remain active for an extended period.
An implant is a physical device placed beneath the skin.
The device would contain medication and release it gradually over time.
The implant would generally require a procedure for placement and potentially another procedure for removal or replacement.
Both approaches aim to reduce dosing frequency, but they involve different technologies and medical procedures.
If future implant technologies demonstrate adequate safety and effectiveness, several potential benefits could emerge.
A long-duration implant could reduce the number of times medication needs to be administered.
This could be particularly useful for people who find daily medication routines difficult.
A controlled-release device could potentially provide relatively steady medication exposure.
Maintaining consistent concentrations may help reduce fluctuations associated with repeated doses.
An implant could reduce the visibility of medication use compared with keeping tablets at home or taking medication regularly.
Privacy can be an important consideration for some people using HIV prevention medicines.
Long-duration delivery could reduce the number of medication-related decisions required throughout the year.
However, clinical follow-up and HIV testing would still remain important.
Developing an HIV prevention implant involves several challenges.
A medical procedure would be required to insert the device beneath the skin.
This introduces considerations such as discomfort, infection risk, scarring, bleeding, and proper positioning.
Depending on the design, the device may eventually need to be removed.
A removal procedure could create additional inconvenience compared with an injection.
The implant must release medication at a predictable rate.
Too little medication could result in inadequate protection, while excessive exposure could increase the risk of side effects.
A device that remains beneath the skin for months or years requires careful evaluation of local tissue reactions and systemic effects.
HIV prevention requires careful attention to drug concentrations.
If HIV infection occurs while an antiretroviral drug remains in the body at levels that are too low to fully suppress the virus, resistance could potentially develop.
This makes HIV testing and appropriate clinical monitoring essential.
HIV testing is a fundamental part of PrEP care.
PrEP is intended for people who are HIV negative. If someone has an undiagnosed HIV infection, prevention medication alone does not provide the complete combination treatment required for HIV management.
CDC emphasizes that testing is the only way to determine HIV status.
HIV testing also remains important during ongoing prevention care.
A negative result does not always immediately exclude a very recent infection because tests have window periods. The timing and type of testing therefore matter when evaluating recent exposure.
No.
HIV prevention medicines specifically target HIV infection.
They do not prevent sexually transmitted infections such as:
Condoms can provide protection against HIV and several other sexually transmitted infections when used correctly.
Other preventive measures, including vaccination and routine sexual-health screening, may also be appropriate depending on individual circumstances.
HIV prevention can be particularly important during pregnancy because HIV infection can affect both the pregnant person and the infant.
The choice of PrEP medicine during pregnancy or breastfeeding requires individualized medical assessment.
Long-acting medicines may remain in the body for extended periods, so pregnancy planning and reproductive considerations can be important when selecting a prevention strategy.
Medical professionals can assess the balance between HIV exposure risk, medication characteristics, and pregnancy-related considerations.
Long-acting prevention does not eliminate the importance of adherence.
For injectable PrEP, appointments must occur according to the prescribed schedule.
For a future implant, the device would also need to be replaced or removed according to its intended duration.
If a scheduled dose is missed or an implant reaches the end of its drug-release period, additional prevention measures may be necessary while the next PrEP strategy is arranged.
The appropriate response depends on the specific medication, timing, and potential HIV exposure.
PrEP is taken before potential exposure to HIV.
PEP, or post-exposure prophylaxis, is used after a possible exposure.
PEP is time-sensitive and should be started as soon as possible after a potential exposure. HIV.gov notes that PEP should be started within 72 hours of exposure.
A long-acting PrEP injection or future implant is therefore not a substitute for emergency evaluation after an exposure when PEP may be indicated.
No prevention method provides protection against every possible exposure.
However, several highly effective tools can substantially reduce HIV transmission.
These include PrEP, PEP, condoms, sterile injection equipment, HIV testing, and effective HIV treatment.
People living with HIV who maintain an undetectable viral load through effective treatment do not transmit HIV through sex.
Combining appropriate prevention measures can provide broader protection than relying on one method alone.
Research into long-acting drug delivery is part of a broader effort to make HIV prevention easier to maintain.
The progression from daily oral PrEP to long-acting injectable medicines demonstrates how HIV prevention technology has evolved.
Future implant systems could potentially extend the duration of protection even further if researchers can develop devices that safely release appropriate amounts of medication over long periods.
Such technologies would need to demonstrate effectiveness, safety, predictable drug release, ease of placement and removal, and acceptable long-term tolerability before becoming part of routine HIV prevention care.
The term “HIV protection implant” can create confusion because it may refer to experimental implant technology, long-acting HIV prevention in general, or injectable PrEP.
At present, long-acting injectable PrEP is the more established technology.
Lenacapavir, for example, represents a major advance in HIV prevention but is delivered through scheduled injections rather than a subcutaneous implant.
Clear terminology helps distinguish established medical treatments from technologies still undergoing research.
HIV prevention implants are designed around the concept of placing a drug-delivery device beneath the skin and releasing antiretroviral medication over an extended period.
They are different from long-acting HIV prevention injections.
Current HIV prevention approaches include oral PrEP, injectable cabotegravir, and injectable lenacapavir, along with other prevention strategies. WHO recognizes long-acting injectable lenacapavir and cabotegravir among PrEP methods.
Lenacapavir is particularly notable because its prevention regimen uses twice-yearly injections, offering a much longer dosing interval than daily oral PrEP.